Biotech Unusual Volume: Reliv International (NASDAQ:RELV), Transcept Pharmaceuticals (NASDAQ:TSPT), Aastrom Biosciences (NASDAQ:ASTM), Bacterin International Holdings (NYSEMKT:BONE)

Reliv International, Inc. (NASDAQ:RELV) a maker of nutritional supplements that promote optimal health, on March 5 reported its financial results for the fourth quarter and full year of 2013. Reliv International, Inc. (NASDAQ:RELV) stock performance was 2.05% in last session and finished the day at $2.02. Traded volume was 38,868.00 shares in the last session and the average volume of the stock remained 11,999.00 shares. The beta of the stock remained 1.35. Reliv International, Inc. (NASDAQ:RELV) insider ownership is 0.20%.

On March 13, 2014, Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT) issued a press release relating to its financial results for the three months and full year ended December 31, 2013 and certain other information. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) rose 5.00% to $3.15 yesterday on volume of 204,805.00 shares. The intra-day range of the stock was $2.95 – $3.19. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) has a market capitalization of 59.16 million.

Aastrom Biosciences, Inc. (NASDAQ:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, yesterday announced that Nick Colangelo, President and CEO of Aastrom, will present at the 2014 Regen Med Investor Day on Wednesday, March 26 at 3:15 p.m. EDT at the Metropolitan Club in New York City.
Aastrom Biosciences Inc. (NASDAQ:ASTM)’s stock on March 19, 2014 reported a higher of 6.72% to the closing price of $3.97. Its fifty two weeks range is $3.14 – $25.09. The total market capitalization recorded 12.08 million. The overall volume in the last trading session was 580,614.00 shares. In its share capital, Aastrom Biosciences Inc. (NASDAQ:ASTM) has 3.04 million outstanding shares.

Bacterin International Holdings (NASDAQ:BONE) posted its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01, Stock Ratings reports. The company had revenue of $8.30 million for the quarter, compared to the consensus estimate of $8.00 million. On Wednesday, shares of Bacterin International Holdings Inc. (NYSEMKT:BONE) advanced 6.46% to close the day at $0.840. Company return on investment (ROI) is -25.70% and its monthly performance is recorded as 44.83%. Bacterin International Holdings Inc. (NYSEMKT:BONE) quarterly revenue growth is 121.05%.